A detailed history of Swiss National Bank transactions in Altimmune, Inc. stock. As of the latest transaction made, Swiss National Bank holds 139,500 shares of ALT stock, worth $969,525. This represents 0.0% of its overall portfolio holdings.

Number of Shares
139,500
Previous 139,500 -0.0%
Holding current value
$969,525
Previous $927,000 7.66%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

BUY
$5.91 - $10.23 $197,985 - $342,705
33,500 Added 31.6%
139,500 $927,000
Q1 2024

May 07, 2024

BUY
$8.22 - $13.81 $871,320 - $1.46 Million
106,000 New
106,000 $1.08 Million
Q1 2023

May 10, 2023

SELL
$4.19 - $16.83 $51,118 - $205,325
-12,200 Reduced 10.31%
106,100 $447,000
Q4 2022

Feb 08, 2023

BUY
$8.74 - $16.45 $1.03 Million - $1.95 Million
118,300 New
118,300 $1.95 Million

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $341M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Swiss National Bank Portfolio

Follow Swiss National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.